Okadaic acid mediates p53 hyperphosphorylation and growth arrest in cells with wild-type p53 but increases aberrant mitoses in cells with non-functional p53

Carcinogenesis

Volumn 20, Issue 6, 1999, Pages 1043-1048

  Milczarek, Gavin J ^a   Chen, Weixing ^a   Gupta, Ashok ^a   Martinez, Jesse D ^a   Bowden, G Tim ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKADAIC ACID; OLIGONUCLEOTIDE; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN P21; PROTEIN P53; TUMOR PROMOTER;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; CONTROLLED STUDY; EMBRYO; FIBROBLAST; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RAT; TEMPERATURE; TRANSGENE; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA PRIMERS; G2 PHASE; MITOSIS; OKADAIC ACID; PEPTIDE MAPPING; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RATS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033018236     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.6.1043     Document Type: Article

References (38)

1. El-deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W. and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
2. Levine, A.J. (1997) p53 the cellular gatekeeper for growth and division. Cell, 88, 323-331.
3. Vogelstein, B. (1990) A deadly inheritance. Nature, 348, 681-682.
4. Steegenga, W.T., van der Eb, A.J. and Jochemsen, A.G. (1996) How phosphorylation regulates the activity of p53. J. Mol. Biol, 263, 103-113.
5. Milczarek, G.J., Martinez, J.D. and Bowden, G.T. (1997) p53 phosphorylation: biochemical and functional consequences. Life Sci., 60, 1-11.
6. Fujiki, H., Sueoka, E., Komori, A. and Suganuma, M. (1997) Tumor promotion and TNF-α gene expression by the okadaic acid class tumor promoters. Environ. Carcinog. Ecotoxicol. Rev., C15, 1-40.
7. Schonthal, A.H. (1995) Regulation of gene expression by serine/threonine protein phosphatases. Semin. Cancer Biol., 6, 239-248.
8. Yatsunami, J., Komori, A., Ohta, T., Suganuma, M. and Fujiki, H. (1993) Hyperphosphorylation of retinoblastoma protein and p53 by okadaic acid, a tumor promoter. Cancer Res., 53, 239-241.
9. Fuchs, B., Hecker, D. and Scheidtmann, K.H. (1995) Phosphorylation studies on rat p53 using the baculovirus expression system manipulation of the phosphorylation state with okadaic acid and influence on DNA binding. Eur. J. Biochem., 228, 625-639.
10. Lohrum, M. and Scheidmann, K.H. (1996) Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene, 13, 2527-2539.
11. Skouv, J., Jensen, P.O., Forchhammer, J., Larsen, J.K. and Lund, L.R. (1994) Tumor-promoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle. Cell Growth Differ., 5, 329-340.
12. Zhang, W., Mcclain, C., Gau, J.P., Guo, X.Y. and Deisseroth, A.B. (1994) Hyperphosphorylation of p53 induced by okadaic acid attenuates its transcriptional activation function. Cancer Res., 54, 4448-4453.
13. Hecker, D., Page, G., Lohrum, M., Weiland, S. and Scheidmann, K.H. (1996) Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene, 12, 953-961.
14. Yan, Y., Shay, J.W., Wright, W.E. and Mumby, M.C. (1997). Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation. J. Biol. Chem., 272, 15220-15226.
15. Martinez, J.D., Georgoff, I., Martinez, J. and Levine, A.J. (1991) Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev., 5, 151-159.
16. Martinez, J.D., Craven, M.T., Joseloff, E., Milczarek, G.J. and Bowden, G.T. (1997) Regulation of DNA binding and transactivation in p53 by nuclear localization and phosphorylation. Oncogene, 14, 2511-2520.
17. Hinds, P., Finlay, C. and Levine, A.J. (1989) Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol, 63, 739-746.
18. Herschman, H.R., Lim, W., Brankow, D.W. and Fujiki, H. (1989) The tumor promoters 12-O-tetradecanoylphorbol-13-acetate and okadaic acid differ in toxicity, mitogenic activity and induction of gene expression. Carcinogenesis, 10, 1495-1498.
19. Luo, K., Hurley, T.R. and Sefton, B.M. (1990) Transfer of proteins to membranes facilitates both cyanogen bromide cleavage and two dimensional proteolytic mapping. Oncogene, 5, 921-923.
20. Boyle, W, J., van der Geer, P. and Hunter, T. (1991) Phosphopeptide mapping and phosphoamino acid analysis by two dimensional separation on thin layer cellulose plates. Methods Enzymol, 201, 110-149.
21. Ausubel, F.W. (ed.) (1994) Current Protocols in Molecular Biology. Vols 1-3. John Wiley and Sons Inc. New York, NY, USA.
22. Gannon, J.V., Greaves, R., Iggo, R. and Lane, D.P. (1990) Activating mutations in p53 produce a common conformational effect: A monoclonal antibody specific for the mutant form. EMBO J., 9, 1595-1602.
23. Rotter, V., Witte, O.N., Coffman, R. and Baltimore, D. (1980) J. Virol., 36, 547-555.
24. Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem., 162, 156-159.
25. Knippschild, U., Milne, D., Campbell, L. and Meek, D. (1996) p53 N-terminus targeted protein kinase activity is stimulated in response to wild-type p53 and DNA damage. Oncogene, 13, 1387-1393.
26. Fuchs, B., O'Connor, D., Fallis, L., Scheidtmann, K.H. and Lu, X. (1995) p53 phosphorylation mutants retain transcriptional activity. Oncogene, 10, 789-793.
27. Mayr, G.E., Reed, M., Wang, P., Wang, Y., Schwedes, J. and Tegtmeyer, P. (1995) Serine phosphorylation in the N-terminus of p53 facilitates transactivation. Cancer Res., 55, 2410-2417.
28. Latham, K.M., Eastman, S.W., Wong, A. and Hinds, P.W. (1996) Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases. Mol. Cell Biol., 16, 4445-4455.
29. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl Acad. Sci. USA, 92, 8493-8497.
30. Ludlow, J.W. and Nelson, D.A. (1995) Control of activity of type 1 serine/ threonine protein phophatase during the cell cycle. Semin. Cancer Biol., 6, 195-202.
31. Nelson, D.A., Krucher, N.A. and Ludlow, J.W. (1997) High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. J. Biol. Chem., 272, 4528-4535.
32. Lee, W.H., Chen, P.L. and Riley, D.J. (1995) Regulatory networks of the retinoblastoma protein. Ann. NY Acad. Sci., 752, 432-445.
33. Zhai, Y., Wirth, J., Kang, S., Welsch, C.W. and Essleman, W.J. (1995) LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells. Mol. Carcinog., 14, 103-110.
34. Scheidtmann, K.H., Mumby, M.C, Rundell, K. and Walter, G. (1991) Dephosphorylation of simian virus 40 large T antigen and p53 protein by protein phosphatase 2A: inhibition by small T antigen. Mol. Cell Biol., 11, 1996-2003.
35. Fujiki, H. (1992) Is the inhibition of protein phosphatase 1 and 2A activities a general mechanism of tumor promotion in human cancer development? Mol. Carcinog., 5, 91-94.
36. Wyille, A. (1997) Clues in the p53 murder mystery. Nature, 389, 237-238.
37. Hartwell, L. (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71, 543-546.
38. Huang, A., Gandour-Edwards, R., Rosenthal, S.A., Siders, D.B., Deitch, A.D. and White, R.W.D. (1998) p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology, 51, 346-351.